Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Half year trading update

4 Jul 2008 07:00

RNS Number : 3113Y
Cello Group plc
04 July 2008
 



4 July 2008

Cello Group plc

Trading update - six months to 30 June 2008

Cello Group plc ("CelloAIM: CLL), the research and consulting group, today provides the following trading update for the six months to 30 June 2008

The Group has continued to make good progress across both of its operating divisions during the first half of 2008, with healthy like-for-like operating income growth. The Group will therefore deliver headline first half profits in line with expectations.

Divisional Trading

Our research and consulting business has performed well in the first six months. Most notably, our healthcare and public sector practices (which comprise approx 33% of the operating income of the Group) have delivered encouraging levels of growth and have a healthy pipeline going into the second half. Our consumer research businesses have also made an excellent contribution with growth being aided by a number of significant new international client wins and new continuous research projects.

We have continued our organic, client led international growth plan with the establishment of an office in San Francisco and we plan to open shortly in Germany. We have also continued our investment in digital and online research initiatives. Notwithstanding this investment, the Group expects its underlying operating margins in this division to be maintained at previous full year levels.

Our response business, which was rebranded as Tangible Group at the start of the year, has also performed well in the first half. The business is traditionally second half weighted as a substantial number of our charity clients have marketing budgets with a significant second half bias. Revenue visibility from such clients is generally very good. The division also has a growing number of public sector clients with committed spend. Our financial services clients continue to migrate budget to the more accountable elements of marketing spend. The Group expects underlying operating margins in this division to be at least one percentage point higher than the comparable period in 2007.

Headcount

The overall headcount of the Group has risen by 3% in the first six months of the year to over 820 peopleWe have invested in our growing digital, data, and UK qualitative research businesses. In some other areas of the Group headcount has been reduced as a matter of due prudence given the general economic outlookAs part of our regular review of our fixed cost structure, we have reduced annualised salary costs by £1.0m at a cost of £0.5m during the first half

Debt and Earn Out Obligations

In line with the Group's prudent funding policy, we have maintained a relatively low level of net debt and future cash obligations under earn out commitments. We expect net debt at 30 June 2008 to be c.£15.0m, and well within our agreed banking facilities.

In April 2008, the Group settled £14.4m of earn out and deferred consideration payments to over 80 vendors and employees of businesses acquired in 2004 and also some deferred initial consideration in respect of an acquisition made in 2007. This was satisfied by the payment of £8.0m in cash or loan notes and the issue of 5.6m shares at 114.5p.

Following this substantial settlement, the Group estimates that its future earn out liabilities have almost halved since 31 December 2007 to around £15.0m. The Group estimates that these future earn out obligationspayable between 2009 and 2013, will be settled by a minimum of £5.8m payable in loan notes and up to £9.2m payable by the issue of new shares.

Full Year Outlook

As stated at the time of the Annual General Meeting on 20 May 2008, the board is mindful of the macro economic environment and its potential impact on our business. We have good revenue visibility for the next quarter and subject to further conversion of existing opportunities and market conditions, we remain cautiously optimistic for the full year. We continue to actively manage our cost base across the Group.

We plan to announce our interim results on Tuesday 17 September 2008 and will further update the market on the trading outlook for the full year at that time.

Enquiries: 

Cello Group plc

 020 7812 8460

Kevin Steeds, Executive Chairman

Mark Scott, Chief Executive Officer

Mark Bentley, Finance Director

 

 

Kaupthing Singer and Friedlander Capital Markets 

 020 3205 5005

Nicholas How

Marc Young

 

 

 

College Hill

 020 7457 2020

Adrian Duffield/Rozi Morris

Notes to Editors (www.cellogroup.co.uk)

Cello is a market research and consulting group that listed on AIM in November 2004. The Group's strategy is to create value for shareholders by building a portfolio of research and consulting businesses capable of advising blue chip clients globally.

Cello has annualised turnover in excess of £130moperating income of over £70m and employs over 820 professional staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXXDEDAPEFE
Date   Source Headline
6th Jul 20204:59 pmPRNForm 8.3 - Cello Health Plc
6th Jul 20203:45 pmRNSForm 8.3 - Cello Health plc
6th Jul 20203:13 pmRNSForm 8.3 - CELLO HEALTH PLC
6th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
6th Jul 202012:15 pmRNSForm 8.3 - Cello Health Plc
6th Jul 20207:00 amRNSUpdate on irrevocable undertakings
3rd Jul 20203:20 pmRNSForm 8.3 - Cello Health
3rd Jul 20203:16 pmRNSForm 8.3 - CELLO HEALTH PLC
3rd Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
3rd Jul 20202:30 pmRNSForm 8.3 - Cello Health PLC
3rd Jul 202011:53 amRNSForm 8.3 - Cello Health Plc
3rd Jul 20209:36 amRNSForm 8.3 - Cello Health Plc
3rd Jul 20207:00 amRNSReplacement - Form 8 (OPD) - Cello Health plc
3rd Jul 20207:00 amRNSForm 8.3 - Cello Health PLC
2nd Jul 20206:26 pmRNSForm 8.3 - Cello Health plc
2nd Jul 20203:20 pmRNSForm 8.3 - Cello Health
2nd Jul 20202:29 pmRNSForm 8.3 - CELLO GROUP PLC
2nd Jul 20201:07 pmRNSForm 8.3 - Cello Health Plc
2nd Jul 202012:17 pmRNSForm 8.3 - Cello Health Plc
2nd Jul 202010:57 amRNSForm 8.3 - CELLO HEALTH PLC
2nd Jul 202010:26 amGNWForm 8.3 - [Cello Health plc - Opening Declaration] - (HH Ltd)
2nd Jul 202010:25 amRNSForm 8.3 - Cello Health Plc
2nd Jul 20208:53 amRNSForm 8.5 (EPT/NON-RI)
2nd Jul 20207:00 amRNSUpdate on letters of intent
2nd Jul 20207:00 amRNSForm 8 (OPD) - Cello Health plc
1st Jul 20205:21 pmGNWForm 8.3 - Cello Health plc
1st Jul 20203:31 pmPRNForm 8.3 - Cello Health
1st Jul 20209:05 amRNSForm 8.3 - Cello Health plc
1st Jul 20207:00 amRNSRECOMMENDED CASH OFFER
15th Jun 202010:09 amRNSHolding(s) in Company
11th Jun 20203:48 pmRNSHolding(s) in Company
20th May 20201:05 pmRNSResult of AGM
20th May 20207:00 amRNSAGM Statement
5th May 20207:00 amRNSIssue of Equity
21st Apr 20207:00 amRNSAnnual Report and Notice of AGM
17th Apr 20209:46 amRNSTotal Voting Rights
14th Apr 20205:18 pmRNSHolding(s) in Company
7th Apr 20207:00 amRNSCOVID-19 Update
30th Mar 20209:37 amRNSGrant of Options
18th Mar 20207:00 amRNSPreliminary Results
7th Feb 202012:19 pmRNSHolding(s) in Company
6th Feb 20207:00 amRNSSettlement with Access Intelligence
22nd Jan 20204:40 pmRNSBlock listing Interim Review
16th Jan 20207:00 amRNSPre-Close Trading Statement
3rd Dec 20193:09 pmRNSTotal Voting Rights
22nd Nov 20194:55 pmRNSHolding(s) in Company
14th Nov 20199:30 amRNSHolding(s) in Company
13th Nov 20195:00 pmRNSTotal Voting Rights
7th Oct 20191:39 pmRNSHolding(s) in Company
7th Oct 20191:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.